【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，非下述情況之老年病患，不建議使用超過八周：潰瘍高風險族群(如長期使用口服類固醇、NSAID)、糜爛性食道炎(EE)、胃酸分泌過多、無法使用H2 antagonist者。

PPI Gastric and duodenal ulcers, moderate and severe reflux esophagitis; pathological gastric hyper-secretion

Pantoprazole is a potent inhibitor of gastric acid secretion. Animal and in vitro studies have demonstrated it to be comparable to or more potent than omeprazole, with less potential for interactions with P450 cytochromes and better acid stability.

Pantoprazole is well absorbed. It undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%. Protein binding: 98%. Metabolism: Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. After administration of a single intravenous dose of 14C-labeled pantoprazole to healthy, normal metabolizer subjects, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion. Half life: 1 hour.

Hypersensitivity to pantoprazole; Severe hepatic insufficiency; Cirrhosis

B

Pantoprazole is distributed into milk; discontinue nursing or the drug because of potential risk in nursing infants.

headache (1.3%), diarrhea (1.5%), dizziness (0.7%), pruritis (0.5%), and asthenia (0.3%)

Adults: gastric ulcer, duodenal ulcer and reflux esophagitis: 40mg IV QD for 7-10 days; pathological gastric hyper-secretion: 80 mg IV Q12H, may increase to Q8H, MAX 240 mg/day. Dosage reductions are not necessary for patients with renal insufficiency or on dialysis, the maximum daily dose 40 mg

Reconstituted with N/S